Drug Details

General Information of the Drug (ID: DR8802)
Name
Idoxuridine
Synonyms
idoxuridine; 5-Iodo-2'-deoxyuridine; 54-42-2; 5-Iododeoxyuridine; Idoxuridin; Iododeoxyridine; Iodoxuridine; (+)-5-Iodo-2'-deoxyuridine; 2'-Deoxy-5-iodouridine; IDUR; IUDR; Joddeoxiuridin; Herplex; Allergan 211; Virudox; 5IUDR; Idoxuridinum; Idoxuridina; Dendrid; Allergan 201; IDU; 5-Iodouracil deoxyriboside; Idossuridina [DCIT]; IdUrd; 5-IUDR; Idoxene; Stoxil; Iduridin; Kerecid; 1-(2-Deoxy-beta-D-ribofuranosyl)-5-iodouracil; 5IdU; 1beta-D-2'-Deoxyribofuranosyl-5-iodouracil; 1-beta-D-2'-Deoxyribofuranosyl-5-iodouracil; SK&F-14287; MFCD00134656; NSC-39661; URIDINE, 2'-DEOXY-5-IODO-; Allergan-211; UNII-LGP81V5245; CHEBI:147675; 1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-iodopyrimidine-2,4(1H,3H)-dione; (+)-5-Iodo-2-deoxyuridine; Antizona; Heratil; LGP81V5245; SK&F 14287; ID2; Iduoculos; DSSTox_CID_25238; DSSTox_RID_80769; DSSTox_GSID_45238; Idoxuridinum [INN-Latin]; ent-Idoxuridine; Idoxuridina [INN-Spanish]; (+)-5-Iodo-2 -deoxyuridine; Idossuridina; C9H11IN2O5; 5-Iododesoxyuridine; 5-Iodo-deoxyuridine; (+)-5-Iodo-2'-deoxyuridine, 99%; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; uridine, 2'-deoxy-5-(iodo-131I)-; CCRIS 2827; SR-05000001510; EINECS 200-207-8; BRN 0030397; AI3-50861; HSDB 7479; CAS-54-42-2; NCGC00016243-01; Dendrid (TN); Uracil, 5-iodo-1-(2-deoxy-beta-D-ribofuranosyl)-; Idoxuridine [USAN:USP:INN:BAN:JAN]; 5-iodo-2'deoxyuridine; Idoxuridine (5-IdU); PubChem14202; HERPLEX (TN); Prestwick3_000018; CHEMBL788; Epitope ID:138107; 5-I-2'-dUrd; SCHEMBL3683; 2???-Deoxy-5-iodouridine; BSPBio_000055; 4-24-00-01235 (Beilstein Handbook Reference); MLS002154175; 5-IODO-2-DEOXYURIDINE; BPBio1_000061; Idoxuridine (JP17/USP/INN); DTXSID2045238; SCHEMBL15850897; AOB5602; HMS2090M10; HMS2095C17; HMS2230E10; HMS3712C17; BCP29428; HY-B0307; ZINC3834173; 5-IUdR; IDU; IdUrd; Idoxuridine; Tox21_110324; ANW-32073; BDBM50370388; s1883; AKOS015920431; Tox21_110324_1; (+)-5-Iodo-2'-deoxyuridine, 98%; AC-8219; CCG-220018; DB00249; MCULE-5585466189; SMP2_000072; NCGC00179673-01; NCGC00179673-03; AS-13469; I381; SMR001233472; Idoxuridine 100 microg/mL in Acetonitrile; AB0013659; DB-009133; 5-Iodo-2'-deoxyuridine, >=99% (HPLC); I0258; SW198484-2; 1-(2-Deoxy-??-D-ribofuranosyl)-5-iodouracil; 1-(2-Deoxy-ss -D-ribofuranosyl)-5-iodouracil; C-1149; D00342; 16509-EP2281563A1; 16509-EP2316459A1; 20495-EP2272827A1; 20495-EP2298768A1; 20495-EP2314585A1; 5-Iodo-2 inverted exclamation marka-deoxyuridine; 134I656; Q409765; J-009907; J-700180; SR-05000001510-1; SR-05000001510-3; SR-05000001510-4; BRD-K76634210-001-14-7; Idoxuridine, European Pharmacopoeia (EP) Reference Standard; Idoxuridine, United States Pharmacopeia (USP) Reference Standard; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodo-1,2,3,4-tetrahydropyrimidine-2,4-dione; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-iodo-pyrimidine-2,4-dione; 889872-67-7
    Click to Show/Hide
Molecular Type
Small molecule
Disease Herpes simplex infection [ICD-11: 1F00] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C9H11IN2O5
PubChem CID
5905
Canonical SMILES
C1C(C(OC1N2C=C(C(=O)NC2=O)I)CO)O
InChI
1S/C9H11IN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1
InChIKey
XQFRJNBWHJMXHO-RRKCRQDMSA-N
CAS Number
CAS 54-42-2
ChEBI ID
CHEBI:147675
TTD Drug ID
D09PZO
DrugBank ID
DB00249
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Cidofovir      Homo sapiens     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model Chick embryo fibroblasts infected with Bratislava and RIIPD strains Microorganism model Gallus gallus
                    Experimental
                    Result(s)		 The combined effect of CDV and IUdR on VV replication in monolayer CEF cultures was characterized as a markedly synergistic one.
Target and Pathway
Target(s) Virus Deoxyribonucleic acid (Viru DNA)  Molecule Info  [3]
References
Reference 1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 014169.
Reference 2 Synergistic combination effect of cidofovir and idoxuridine on vaccinia virus replication. Antivir Chem Chemother. 2006;17(2):53-8.
Reference 3 Radiopharmaceuticals (Strontium 89) and radiosensitizers (idoxuridine). J Intraven Nurs. 1998 Nov-Dec;21(6):335-7.
 Download Picture         KEGG Link